Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
Angela Y Moore, Blakely S RichardsonArlington Center for Dermatology, Arlington, Texas, USAAbstract: Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Tr...
Main Authors: | Angela Y Moore, Blakely S Richardson |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-04-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Online Access: | http://www.dovepress.com/long-term-use-of-adalimumab-in-the-treatment-of-moderate-to-severe-pla-a4267 |
Similar Items
-
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-07-01) -
Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023-06-01) -
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-10-01) -
Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
by: Nicolazzo D, et al.
Published: (2014-06-01) -
Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01)